Predictive Oncology Inc. AIPT Income Statement

Predictive oncology inc. (AIPT)

Income statement / Quarterly

Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Revenue
347	522	286	255	311	329	358	411	220	152	106	175	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of goods sold
131	208	118	73	106	83	108	117	60	28	22	36	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	134	85	96	183	85	234	151	165	397	318	70	58	107	150	150	89	51	24	22	73	20	2	0	0	-
Cost of goods sold
-	-	-	-	-	-	-	-	-	-	-	-	-	26	36	85	104	19	83	95	121	134	98	31	28	26	67	67	43	69	1	13	43	11	1	0	0	-
Gross margin
215	314	167	181	205	246	249	294	159	123	84	138	107	108	48	11	78	66	150	55	44	262	219	39	29	81	83	83	46	-18	23	8	30	9	0	0	0	0
General and administrative expense
2,355	2,616	3,310	1,497	1,892	762	729	1,241	81	621	2,214	1,132	490	733	2,262	1,688	1,809	861	856	-127	1,635	737	1,330	1,179	2,558	3,195	888	888	1,251	2,518	1,950	565	2,546	428	272	312	381	438
Operations expense
514	707	1,271	466	470	723	378	287	839	192	182	200	230	292	244	390	471	202	151	21	232	183	291	265	333	354	204	204	242	300	148	69	-50	135	175	91	55	44
Sales and marketing expense
238	434	685	554	643	621	554	550	414	301	231	147	119	137	102	108	64	66	139	233	328	325	319	204	196	164	108	108	98	13	29	31	83	60	68	19	36	67
Total operating loss
-	-3,444	-5,098	-	-	-1,861	-1,412	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on revaluation of cash advances to Helomics
-	-	1,222	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income
-	-	-3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Expense
-	-	-819	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total operating loss
-	-	-	2,337	-	-	-	1,785	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income
-	15	-	53	-	-	-	27	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other expense
-	578	-	569	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-3	51	189	153	212	131	14	18	-24	407	126	126	90	23	89	55	53	61	57	57	33	59
Loss (gain) on valuation of equity-linked financial instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	11	-46	65	69	69	-81	18	58	0	-365	23	186	4	348	563
Total Expense
-	-	-	-	-	-	-	-	-	1,115	2,628	1,480	839	1,163	2,609	2,187	2,341	1,182	1,335	281	-	1,377	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on equity method investment
0	0	0	-439	-	-645	-960	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on revaluation of equity method investment
-	-	6,164	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-4,008	1,465	-	-	-2,506	-2,373	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividend on Series E Convertible Preferred Stock
-	125	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Expense
-	-	-	-	-	-	-	-	-	1,115	2,628	1,480	-	1,163	2,609	-	-	-	-	-	-	1,377	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,955	1,656	3,110	4,056	1,259	1,259	1,763	2,837	2,159	722	2,998	663	388	477	158	46
Net loss attributable to common shareholders
-13,697	-4,134	1,444	-3,293	-3,446	-2,506	-2,373	-1,760	-1,125	-992	-2,543	-1,341	-732	-1,055	-2,561	-2,176	-2,263	-1,116	-1,185	-225	-2,365	-1,115	-1,735	-1,616	-3,080	-3,974	-1,175	-1,175	-1,717	-2,855	-2,135	-713	-2,967	-654	-388	-477	-158	-46
Gain/(loss) per common share - basic (in dollars per share)
-	-	0.05	-	-	-	-0.20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain/(loss) per common share – diluted (in dollars per share)
-	-	0.02	-	-	-	-0.20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average shares used in computation - basic (in shares)
-	-	29,609	-	-	-	11,878	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average shares used in computation - diluted (in shares)
-	-	60,070	-	-	-	11,878	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized gain from marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-1	3	2	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
-	-	-	-	-	-	-	-	-	-992	-2,543	-1,341	-735	-1,056	-2,558	-2,173	-	-	-1,185	-225	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss per common share - basic and diluted (in dollars per share)
-	-1.31	-	-0.21	-	-1.89	-	-0.15	-0.16	-0.16	-0.41	-0.21	1.97	-0.32	-0.95	-3.01	-23.34	-7.09	-0.36	-0.07	-55.63	-0.37	-0.58	-0.55	-2.44	-2.18	-0.01	-0.01	-0.01	-0.04	-0.04	-0.02	-0.11	-0.02	-0.02	-0.03	-0.01	0.00
Weighted average shares used in computation - basic and diluted (in shares)
-	3,146	-	15,731	-	1,325	-	11,383	6,600	6,232	6,167	6,450	4,554	3,320	2,695	723	-5,900	157	3,263	3,100	-8,423	2,984	2,968	2,949	-236,251	1,821	121,267	121,267	111,562	79,467	54,656	32,664	-	27,236	22,669	-	-	-
Weighted average shares used in computation - basic and diluted (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16,557	13,159	12,353